Nevertheless, prevention of fibrosis is an essential target for the treatment of NASH and cirrhosis34, suggesting a beneficial effect of IGF-I treatment on these conditions. The gene discussed is IGF1; the disease is metabolic dysfunction-associated steatohepatitis.